


Silco Pharmaceuticals Ltd
Un-Audited Financial Statement (Half Yearly)
For the Period from 01 July, 2022 to 31 December, 2022

Silco Pharmaceuticals Limited
Statement of Financial Position (Un-Audited)
As at December 31, 2022

Particulars	Notes	Amount in Taka	
		31 December 2022	30 June 2022
Assets			
Non Current Assets		1,740,750,715	1,670,995,957
Property, Plant and Equipment	3.00	1,574,365,756	1,469,803,663
Right of Use Assets	4.00	1,904,935	3,809,870
Capital Work-in-Progress	5.00	164,480,024	197,382,425
Current Assets		1,036,132,224	1,048,739,867
Inventories	6.00	455,153,792	457,839,504
Trade and Other Receivables	7.00	379,780,891	389,236,460
Advances, Deposits and Prepayments	8.00	143,870,882	137,038,345
Cash and Cash Equivalents	9.00	37,042,416	26,719,260
Investment In Share	10.00	20,284,242	37,906,298
Total Assets		2,776,882,938	2,719,735,824
Shareholders Equity and Liabilities			
Shareholders Equity		2,328,377,477	2,278,623,335
Share Capital	11.00	1,038,070,000	1,038,070,000
Unrealized Gain/Loss on Marketable Securities		(6,365,769)	(10,687,292)
Retained Earnings	12.00	1,296,673,245	1,251,240,627
Non-Current Liabilities		154,890,701	150,207,253
Lease Liabilities (Non Current Portion)			
Deferred Tax Liabilities	13.00	154,890,701	150,207,253
Current Liabilities		293,614,761	290,905,236
Trade and Other Payable	14.00	9,786,260	12,334,060
Lease Liabilities (Current Portion)	15.00	2,100,522	4,112,546
Payable to IPO Applicants		184,607	184,728
Provision for Expenses	16.00	7,314,073	6,996,585
Liabilities for contribution to WPPF	17.00	8,379,079	9,929,514
Dividend Payables (Unclaimed)	18.00	2,137,756	2,142,006
Provision for income tax	19.00	263,712,464	255,205,797
Total Shareholders Equity and Liabilities		2,776,882,938	2,719,735,824
Net Asset Value (NAV) per Share	27.00	22.43	21.95

The annexed notes form an integral part of these financial statements.



Chairman Managing Director Director Company Secretary Chief Financial Officer

SIGNED IN TERMS OF OUR ANNEXED REPORT OF EVEN DATE

Date: 30 January, 2023
Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income (Un-Audited)
For the period ended December 31, 2022

Particulars	Notes	Amount in Taka			
		01 July 2022 to 31 Dec. 2022	01 July 2021 to 31 Dec. 2021	01 Oct 2022, to 31 Dec. 2022	01 Oct 2021 to 31 Dec. 2021
Turnover	20.00	235,635,899	321,011,511	105,841,159	135,928,990
Less: Cost of Goods Sold	21.00	155,569,860	217,166,176	75,474,799	101,520,131
Gross Profit /(Loss)		80,066,039	103,845,335	30,366,360	34,408,860
Less: Operating Expenses	22.00	39,844,171	47,057,196	20,144,666	21,595,619
Profit from Operation		40,221,868	56,788,139	10,221,694	12,813,240
Less: Financial Expenses	23.00	57,778	153,394	51,169	63,125
Less: Financial Expenses (Lease)		141,749	307,718	60,049	143,926
Non-operation Income	24.00	21,531,529	8,960,347	11,184,237	4,751,780
Profit before Contribution to WPPF		61,553,870	65,287,374	21,294,713	17,357,969
Less: Workers' Profit Participation/Welfare Fund (WPPF)		2,931,137	3,108,923	1,014,034	826,570
Profit before Income Tax		58,622,733	62,178,451	20,280,679	16,531,399
Less: Provision for Income Tax	25.00	13,190,115	13,814,321	4,563,153	3,543,735
Current Tax		8,506,667	11,767,298	1,547,596	2,619,242
Deferred Tax		4,683,448	2,047,023	3,015,557	924,493
Net Profit after Tax (Transferred to CE)		45,432,618	48,364,130	15,717,527	12,987,664
Other Comprehensive Income:					
Unrealized Gain/Loss on Investment		8,529,266	(7,270,698)	4,321,523	(6,135,986)
Total Comprehensive income		53,961,884	41,093,432	20,039,050	6,851,679
Earnings per Share (EPS)	26.00	0.44	0.47	0.15	0.13

The annexed notes form an integral part of these financial statements.

নাইম জাহাঙ্গীর
Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer

Date: 30 January, 2023
Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Changes in Equity (Un-Audited)
For the period ended December 31, 2022

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2022	1,038,070,000	(10,687,292)	1,251,240,627	2,278,623,335
Net Profit/(Loss) during the period	-	-	45,432,618	45,432,618
Unrealized Gain/Loss on Marketable Shares	-	4,321,523	-	4,321,523
Balance as on December 31, 2022	1,038,070,000	(6,365,769)	1,296,673,245	2,328,377,477

Statement of Changes in Equity
For the period ended December 31, 2021

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2021	1,038,070,000	(369,919)	1,230,318,041	2,268,018,123
Net Profit/(Loss) during the period	-	-	48,364,130	48,364,130
Unrealized Gain/Loss on Marketable Shares	-	(7,270,698)	-	(7,270,698)
Balance as on December 31, 2021	1,038,070,000	(7,640,616)	1,278,682,171	2,309,111,555

নাইম জা (তম)
Chairman

Managing Director

Director

Company Secretary

Chief Financial Officer






Date: 30 January, 2023
Place: Dhaka

Silco Pharmaceuticals Limited

Statement of Cash Flows (Un-Audited)

For the period ended December 31, 2022

Particulars	Notes	Amount in Taka	
		01 July 2022 to 31 Dec. 2022	01 July 2021 to 31 Dec. 2021
A. Cash Flows from Operating Activities			
Cash received from Customers	31.00	245,091,468	322,021,546
Cash received from Non-operating income		2,225,287	2,405,307
Cash Paid to Suppliers	32.00	(96,007,584)	(145,349,304)
Cash Paid to Employees	33.00	(31,254,992)	(39,548,504)
Cash Paid to Others	34.00	(30,107,611)	(41,768,739)
Financial Expenses		(57,778)	(153,394)
Income Tax Paid		(5,190,445)	(6,329,464)
Net cash flows from operating activities		84,698,346	91,277,448
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(2,980,960)	(6,537,034)
Cash Received/Payments to/from FDR			-
Cash Payments for Capital Work-in-Progress		(110,485,908)	(8,766,553)
Gain on Investment		19,306,242	6,555,040
Investment in Share		21,943,579	(28,468,973)
Net cash used in investing activities		(72,217,047)	(37,217,520)
C. Cash Flows from Financing Activities			
Refund to IPO Applicants		(121)	
Financial Expenses (Lease)		(141,749)	(307,718)
Principle payment (Lease)		(2,012,023)	(1,846,054)
Cash dividend paid		(4,250)	(47,947)
Net Cash used for financing activities		(2,158,143)	(2,201,719)
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		10,323,156	51,858,209
E. Cash and Cash Equivalents at the beginning of the year		26,719,260	53,031,144
F. Cash and Cash Equivalents at the end of the period (D+E)		37,042,416	104,889,353
Net Operating Cash Flows Per Share (NOCFPS)	28.00	0.82	0.88

 Chairman
 Managing Director
 Director
 Company Secretary
 Chief Financial Officer

Date: 30 January 2023

Place: Dhaka